Join the Psoriasis group to help and get support from people like you.
Psoriasis News (Page 2)
Related terms: Erythrodermic Psoriasis, Guttate Psoriasis, Inverse Psoriasis, Palmo-plantar Psoriasis, Psoriasis vulgaris, Pustular Psoriasis
Biological Agent Trials for Psoriasis Rarely Include Patient Images
FRIDAY, Dec. 29, 2023 – Few randomized controlled trials involving biological agents for psoriasis treatment include patient images, according to a review published online Nov. 15 in the Journal of...
Skin Conditions Flare Up When Wildfires Nearby
TUESDAY, Dec. 26, 2023 – The smoke billowing from this summer’s devastating wildfires wasn’t just bad for your lungs. Skin problems also seem to worsen, with dermatology visits rising as air quality ...
Skin Diseases Pose a Psychosocial Burden
THURSDAY, Nov. 2, 2023 – Skin diseases can cause a psychosocial burden and feelings of stigmatization, according to a study published online Oct. 8 in the Journal of the European Academy of ...
FDA Approves Arcutis’ Zoryve (roflumilast) Cream 0.3% for Treatment of Psoriasis in Children Ages 6 to 11
WESTLAKE VILLAGE, Calif., Oct. 06, 2023 (GLOBE NEWSWIRE) — Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful i...
FDA Approves Sotyktu (deucravacitinib) for the Treatment of Adults with Moderate-to-Severe Plaque Psoriasis
Bristol Myers Squibb’s Sotyktu, a first-in-class, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, is the only approved TYK2 inhibitor worldwide and the first innovation in oral t...
FDA Approves Spevigo (spesolimab-sbzo) for Generalized Pustular Psoriasis (GPP) Flares in Adults
More than half of patients treated with Spevigo (spesolimab-sbzo) injection, for intravenous use showed no visible pustules one week after receiving treatment Spesolimab is a monoclonal antibody...
FDA Approves Zoryve (roflumilast) Cream for the Treatment of Plaque Psoriasis
WESTLAKE VILLAGE, Calif., July 29, 2022 (GLOBE NEWSWIRE) — Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful i...
FDA Approves Vtama (tapinarof) Cream for the Treatment of Plaque Psoriasis in Adults
LONG BEACH, Calif., and BASEL, Switzerland, May 24, 2022 — Dermavant Sciences, a biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology, t...
FDA Approves Otezla (apremilast) for the Treatment of Adult Patients with Plaque Psoriasis, Regardless of Severity Level
THOUSAND OAKS, Calif., Dec. 20, 2021 /PRNewswire/ – Amgen (NASDAQ: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved Otezla® (apremilast) for the treatment of adult ...
Novartis Cosentyx Receives FDA Approval for Treatment of Children and Adolescents with Moderate to Severe Plaque Psoriasis
EAST HANOVER, N.J., June 1, 2021 /PRNewswire/ – Novartis, a leader in immuno-dermatology and rheumatology, today announced the U.S. Food and Drug Administration (FDA) has approved Cosentyx...
FDA Approves Wynzora Cream (calcipotriene and betamethasone dipropionate) for Adults with Plaque Psoriasis
COPENHAGEN, Denmark, July 22, 2020 / B3C newswire / – MC2 Therapeutics, a commercial stage pharmaceutical company developing a new standard of topical therapies for chronic inflammatory conditions,...
Lilly's Taltz (ixekizumab) Receives U.S. FDA Approval for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis
INDIANAPOLIS, March 30, 2020 /PRNewswire/ – Eli Lilly and Company (NYSE: LLY) announced today the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application...
FDA Approves Avsola (infliximab-axxq), a Biosimilar to Remicade
THOUSAND OAKS, Calif., Dec. 6, 2019 /PRNewswire/ – Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved Avsola (infliximab-axxq) for all approved...
FDA Approves RediTrex (methotrexate) for Rheumatoid Arthritis, Juvenile Idiopathic Arthritis, and Psoriasis
NASHVILLE, Tenn., Dec. 2, 2019 /PRNewswire/ – Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, today announced that it has received approval from the U.S. Food and...
FDA Approves Abrilada (adalimumab-afzb), a Biosimilar to Humira
November 18, 2019 - Pfizer Inc. (NYSE: PFE) today announced the United States (U.S.) Food and Drug Administration (FDA) has approved Abrilada™ (adalimumab-afzb), as a biosimilar to Humira® (a...
Further information
Related condition support groups
Plaque Psoriasis, Dermatological Disorders
Related drug support groups
prednisone, methylprednisolone, methotrexate, Humira, clobetasol, triamcinolone, fluocinonide, Remicade, prednisolone, view more... Stelara, Cosentyx, Skyrizi, dexamethasone, adalimumab, etanercept, desonide, halobetasol, Taltz